ArticleNPJ microgravity2026
Label-free blood cell separation for space health monitoring using a portable blast cell biochip.
Article in NPJ microgravity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Separation of Human P63Analytical chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
We demonstrate a novel biomedical application of a commercial spiral microfluidic chip (Fluidic 382), originally developed for particle sorting, by repurposing it for label-free, size-based isolation of pathological blood cells, including leukemic blasts from acute myeloid leukemia (AML) samples. For the first time, we establish and validate a streamlined protocol for cell separation using Dean-driven hydrodynamic forces in a chip not originally designed for blood analysis. Using a 9-turn, 6-outlet spiral channel configuration, we achieved high-efficiency sorting of red and white blood cells from healthy donors and selectively enriched pathological blasts from AML patient blood. The device's performance was validated through flow cytometry and numerical simulations, demonstrating strong agreement between experimental and computational results with less than 1% relative error. With its compact footprint, reagent-free operation, and automation potential, this method represents a significant advance toward point-of-care blood diagnostics in extreme environments, particularly space missions. The chip's ability to separate pathological cells in microgravity-compatible conditions offers a promising route for real-time astronaut health monitoring, supporting early detection and mitigation of radiation-induced haematological disorders such as AML.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.